Natco Pharma receives EIR from USFDA for Vizag facility

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced the successful closure of inspection and received Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam (Vizag), Andhra Pradesh, India, for an inspection conducted during the period from 30th January to 3rd February 2023.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 639.60 as compared to the previous close of Rs. 619.40. The total number of shares traded during the day was 41467 in over 1337 trades.

The stock hit an intraday high of Rs. 643.25 and intraday low of 619.45. The net turnover during the day was Rs. 26349178.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 InspectionClosure EIR USFDA Vizag DrugFormulations ManufacturingFacility